Category: Press Release

2020.03.27

I-Mab Expands Global Out-Licensing and Business Development Efforts

2020.03.23

I-Mab Appoints Gigi Feng as Vice President and Global Head of Corporate Communications

2020.03.13

I-Mab Biopharma Announces Development of TJM2 to Treat Cytokine Release Syndrome Associated with Severe and Critically-Ill Patients with Coronavirus Disease (COVID-19)

2020.01.17

I-MAB Announces Pricing of U.S. Initial Public Offering

2020.01.03

I-Mab Biopharma Announces Dosing of First Patient in a Pivotal Phase 2 Study of TJ202/MOR202 in Multiple Myeloma in Mainland China

2019.11.14

I-Mab Biopharma Receives IND Approval from NMPA to Initiate Clinical Trials for its Anti-GM-CSF Monoclonal Antibody TJM2 in China

2019.10.14

I-Mab Biopharma and MorphoSys Announce IND Clearance to Initiate Clinical Trials of TJ202/MOR202 for the Treatment of Multiple Myeloma in Mainland China

2019.10.04

I-Mab Biopharma Receives IND Approval in China for Proprietary CD73 Antibody TJD5

2019.09.24

I-Mab Biopharma Announces Clinical Collaboration to Evaluate TJC4 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Multiple Cancer Types

2019.09.12

I-Mab Biopharma Expands Global Team, Appoints Neil K. Warma As General Manager of I-Mab U.S.